Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3. Zocilurtatug serves as the targeting antibody component of antibody-drug conjugates (ADCs) and is used in research related to small cell lung cancer and neuroendocrine carcinoma. Recommended isotype control: Human IgG1 kappa, Isotype Control [1] [2].
In Vitro, Antibody-drug conjugates (ADCs) are a novel class of anti-tumor drugs, consisting of three parts: a targeting antibody—which specifically recognizes tumor cell surface antigens and acts as a "navigator"; a linker; and a cytotoxic payload. Zocilurtatug can serve as the targeting antibody component of an ADC, conjugated with a topoisomerase I inhibitor (camptothecin derivative) payload via a cleavable linker to form the complete ADC Zocilurtatug pelitecan. This allows for precise delivery of the cytotoxic payload to DLL3-positive tumor cells, killing tumor cells while minimizing damage to normal cells[1][2].
References:
[1]. American Association for Cancer Research (AACR). Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer. News Release. October 22, 2025.
[2]. Kemper M, et al. Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons. Cancers (Basel). 2025 Jul 7;17(13):2256.
In Vitro, Antibody-drug conjugates (ADCs) are a novel class of anti-tumor drugs, consisting of three parts: a targeting antibody—which specifically recognizes tumor cell surface antigens and acts as a "navigator"; a linker; and a cytotoxic payload. Zocilurtatug can serve as the targeting antibody component of an ADC, conjugated with a topoisomerase I inhibitor (camptothecin derivative) payload via a cleavable linker to form the complete ADC Zocilurtatug pelitecan. This allows for precise delivery of the cytotoxic payload to DLL3-positive tumor cells, killing tumor cells while minimizing damage to normal cells[1][2].
References:
[1]. American Association for Cancer Research (AACR). Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer. News Release. October 22, 2025.
[2]. Kemper M, et al. Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons. Cancers (Basel). 2025 Jul 7;17(13):2256.